Cytosorbents Corporation
CTSO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $49,535 | $49,569 | $67,538 | $181,675 |
| - Cash | $3,280 | $14,131 | $22,145 | $52,138 |
| + Debt | $26,893 | $18,313 | $18,251 | $13,822 |
| Enterprise Value | $73,149 | $53,751 | $63,644 | $143,359 |
| Revenue | $35,595 | $31,085 | $34,689 | $40,109 |
| % Growth | 14.5% | -10.4% | -13.5% | – |
| Gross Profit | $25,126 | $21,953 | $20,733 | $29,061 |
| % Margin | 70.6% | 70.6% | 59.8% | 72.5% |
| EBITDA | -$15,216 | -$27,879 | -$30,003 | -$21,615 |
| % Margin | -42.7% | -89.7% | -86.5% | -53.9% |
| Net Income | -$20,719 | -$29,247 | -$32,813 | -$24,559 |
| % Margin | -58.2% | -94.1% | -94.6% | -61.2% |
| EPS Diluted | -0.38 | -0.65 | -0.75 | -0.57 |
| % Growth | 41.5% | 13.3% | -31.6% | – |
| Operating Cash Flow | -$14,428 | -$21,655 | -$28,234 | -$14,006 |
| Capital Expenditures | -$284 | -$936 | -$6,456 | -$4,281 |
| Free Cash Flow | -$14,712 | -$22,591 | -$34,690 | -$18,287 |